NasdaqCM:DRTSMedical Equipment
Alpha Tau Medical (DRTS) Is Down 7.7% After Reporting 100% Response In Alpha DaRT Combo Study
In July 2026, Alpha Tau Medical reported clinical data showing a 100% objective response rate and encouraging survival outcomes from its Alpha DaRT plus pembrolizumab study in elderly patients with advanced head and neck squamous cell carcinoma, with minimal Alpha DaRT-related toxicity and results presented at a major international cancer conference.
The trial met its pre-specified success threshold under a Simon two-stage adaptive design, allowing early completion of enrollment after more...